泌尿器科学論文
A 欧文
A-a
1 . Matsuo T, Miyata Y, Araki K, Mukae Y, Otsubo A, Ohba K, Sakai H: Efficacy of Tadalafil Therapy and Changes inOxidative Stress Levels in Male Patients with Lower Urinary Tract Symptoms and Overactive Bladder. Low Urin Tract
Symptoms 12(1): 47-53, 2020. doi: 10.1111/luts.12283. (IF: 1.592) ＊2 . Tagami A, Tomita M, Adachi S, Tsuda K, Yamada S, Chiba K, Okazaki N, Yonekura A, Tsujimoto R, Kajiyama S,Matsubayashi S, Miyamoto T, Mochizuki Y, Ohba K, Osaki M: Epidemiological survey and risk factor analysis of dialysisrelated amyloidosis including destructive spondyloarthropathy, dialysis amyloid arthropathy, and carpal tunnel syndrome. JBone Miner Metab 38(1): 78-85, 2020. doi: 10.1007/s00774-019-01028-6. (IF: 2.626) ＊3 . Kawano H, Ando T, Shida Y, Niino D, Maemura K, Kawai K: Isolated left adrenal medullary hyperplasia. J Cardiol Cases
21(1): 16-19, 2020. doi: 10.1016/j.jccase.2019.08.018. (IF: 0.528)
4 . Ito K, Yokomizo A, Tokunaga S, Arai G, Sugimoto M, Akakura K, Hasumi H, Sakai H, Ouraji A, Oki R, Kashiwagi E,Kobori Y, Hirama H, Kitoh H, Uemura H, Hakariya T, Suzuki K : Diagnostic Impacts of Clinical Laboratory Based p2PSA
Indexes on any Grade, Gleason Grade Group 2 or Greater, or 3 or Greater Prostate Cancer and Prostate Specific Antigen
below 10 ng/ml. J Urol 203(1): 83-91, 2020. doi: 10.1097/JU.0000000000000495. (IF: 1.18) ＊5 . Shida Y, Hakariya T, Miyata Y, Sakai H: Three cases of brain metastasis from castration-resistant prostate cancer. Clin.
Case Rep. 8(1): 96-99, 2020. doi: 10.1002/ccr3.2587. (IF: 0.532) ＊6 . Kitamura M, Tateishi Y, Sato S, Ota Y, Muta K, Uramatsu T, Izumo T, Mochizuki Y, Harada T, Funakoshi S, Matsuo T,Tsujino A, Sakai H, Mukae H, Nishino T: Lower serum calcium and pre-onset blood pressure elevation in cerebral
hemorrhage patients undergoing hemodialysis. Clin. Exp. Nephrol. 24(5): 465-473, 2020. doi: 10.1007/s10157-020-018463. (IF: 2.801) ＊7 . Wang M, Hiraki R, Nakamura N, Hayama T, Yasuda T, Miyata Y, Sakai H, Nakashima MN, Nakashima M, Ohyama K:Determination of Gemcitabine in Plasma of Bladder Cancer Patients by Hydrophilic Interaction Chromatography withUltraviolet Detection. J. Chromatogr. Sci. : 2020. doi: 10.1093/chromsci/bmaa020. (IF: 1.618) ＊8 . Osawa T, Kojima T, Hara T, Sugimoto M, Eto M, Takeuchi A, Minami K, Nakai Y, Ueda K, Ozawa M, Uemura M,Miyauchi Y, Ohba K, Suzuki T, Anai S, Shindo T, Kusakabe N, Tamura K, Komiyama M, Goto T, Yokomizo A, Kohei N,Kashiwagi A, Murakami M, Sazuka T, Yasumoto H, Iwamoto H, Mitsuzuka K, Morooka D, Shimazui T, Yamamoto Y,Ikeshiro S, Nakagomi H, Morita K, Tomida R, Mochizuki T, Inoue T, Kitamura H, Yamada S, Ito YM, Murai S, Nishiyama
H, Shinohara N: Oncological outcomes of a multicenter cohort treated with axitinib for metastatic renal cell carcinoma.
Cancer Sci. 111(7): 2460-2471, 2020. doi: 10.1111/cas.14449. (IF: 6.716) ＊9 . Mukae Y, Miyata Y, Nakamura Y, Araki K, Otsubo A, Yuno T, Mitsunari K, Matsuo T, Ohba K, Sakai H: Pathologicalroles of c-Met in bladder cancer: Association with cyclooxygenase-2, heme oxygenase-1, vascular endothelial growth
factor-A and programmed death ligand 1. Oncol. Lett. 20(1): 135-144, 2020. doi: 10.3892/ol.2020.11540. (IF: 2.967) 〇＊10 . Yamakawa N, Yagishita N, Matsuo T, Yamauchi J, Ueno T, Inoue E, Takata A, Nagasaka M, Araya N, Hasegawa D, ColerReilly A,Tsutsumi S, Sato T, Araujo A, Casseb J, Gotuzzo E, Jacobson S, Martin F, Puccioni-Sohler M, TaylorGP, Yamano
Y: Creation and validation of a bladder dysfunction symptom score for HTLV-1-associated myelopathy/tropical spastic
paraparesis. Orphanet J. Rare Dis. 15(1): 175, 2020. doi: 10.1186/s13023-020-01451-3. (IF: 4.123) ＊11 . Tsuji K, Kitamura M, Muta K, Mochizuki Y, Mori T,Sohara E, Uchida S, Sakai H, Mukae H, Nishino T: Transplantation ofa kidney with a heterozygous mutation in the SLC22A12 (URAT1) gene causing renal hypouricemia: a case report. BMCNephrol. 21(1): 282, 2020. doi: 10.1186/s12882-020-01940-4. (IF: 2.388) ＊12 . Miyata Y, Araki K, Ohba K, Mastuo T, Nakamura Y, Yuno T, Mukai Y, Otsubo A, Mitsunari K, Mochizuki Y, Sakai H:
Oral intake of royal jelly improves anti-cancer effects and suppresses adverse events of molecular targeted therapy byregulating TNF-α and TGF-β in renal cell carcinoma: A preliminary study based on a randomized double-blind clinical trial.
Mol. Clin. Oncol. 13(4): 29, 2020. doi: 10.3892/mco.2020.2099. (IF: 1.63) ＊13 . Yuno Y, Miyata M, Matsuo T, Mukae Y, Otsubo A, Mistunari K, Ohba K,Suda T,Saito S, Sakai H: Relationship Between
Stage-specific Embryonic Antigen-4 and Anti-cancer Effects of Neoadjuvant Hormonal Therapy in Prostate Cancer.
Anticancer Res. 40(10): 5567-5575, 2020. doi: 10.21873/anticanres.14569. (IF: 2.48) 〇＊14 . Yuno Y, Miyata Y, Mukae Y, Otsubo A, Mitsunari K, Matsuo T, Ohba K, Sakai H: Mechanisms Underlying the Inhibitionof Tyrosine Kinase Inhibitor-Induced Anorexia and Fatigue by Royal Jelly in Renal Cell Carcinoma Patients and theCorrelation between Macrophage Colony Stimulating Factor and Inflammatory Mediators. Med Sci (Basel) 8(4): 43, 2020.
doi: 10.3390/medsci8040043. (IF: 3.738)
15 . Araki K, Miyata Y, Ohba K, Nakamura Y, Matsuo T, Mochizuki Y, Sakai H: Correction: Oral Intake of Royal Jelly Has
Protective Effects against Tyrosine Kinase Inhibitor-Induced Toxicity in Patients with Renal Cell Carcinoma: ARandomized, Double-Blinded, Placebo-Controlled Trial. <i>Medicines</i>, 2019, <i>6</i>, 2. Medicines (Basel) 7(11):71, 2020. doi: 10.3390/medicines7110071. (IF: 1.889)
16 . Eguchi S, Hidaka M, Natsuda K, Hara T, Kugiyama T, Hamada T, Tanaka T, Ono S, Adachi T,Kanetaka K,Soyama A,
Mochizuki Y, Sakai H: Simultaneous Deceased Donor Liver and Kidney Transplantation in a Human Immunodeficiency
Virus/Hepatitis C Virus -Coinfected Patient With Hemophilia in Japan: A Case Report. Transplant. Proc. 52(9): 2786-2789,
2020. doi: 10.1016/j.transproceed.2020.05.005. (IF: 1.066) ＊17 . Araki K, Miyata Y, Ohba K, Nakamura Y,Matsuo T, Mochizuki Y, Sakai H: Correction: Oral Intake of Royal Jelly Has
Protective Effects against Tyrosine Kinase Inhibitor-Induced Toxicity in Patients with Renal Cell Carcinoma: A
Randomized, Double-Blinded, Placebo-Controlled Trial. Medicines, 2019, 6, 2. Medicines (Basel) 7(11): 71, 2020. doi:
10.3390/medicines7110071. (IF: 1.889)
18 . Miyata Y,Araki K, Ohba K, Mastuo T, Nakamura Y, Yuno T, Mukai Y, Otsubo A, Mitsunari K, Mochizuki Y, Sakai H:Erratum: Oral intake of royal jelly improves anti-cancer effects and suppresses adverse events of molecular targeted therapy
by regulating TNF-α and TGF-β in renal cell carcinoma: A preliminary study based on a randomized double-blind clinical
trial. Mol. Clin. Oncol. 13(6): 78, 2020. doi: 10.3892/mco.2020.2148. (IF: 1.63) ＊A-b
1 . Mastuo T, Miyata Y, Yuno T, Mukae Y, Otsubo A, Mitsunari K, Ohba K, Sakai H: Molecular Mechanisms of the AntiCancer Effects of Isothiocyanates from Cruciferous Vegetables in Bladder Cancer. Molecules 25(3): 575, 2020. doi:10.3390/molecules25030575. (IF: 4.148) ＊2 . Miyata Y, Mukae Y, Harada J, Matsuda T, Mitsunari K, Matsuo T, Ohba K, Sakai H: Pathological and Pharmacological
Roles of Mitochondrial Reactive Oxygen Species in Malignant Neoplasms: Therapies Involving Chemical Compounds,
Natural Products, and Photosensitizers. Molecules 25(22): 5252, 2020. doi: 10.3390/molecules25225252. (IF: 4.411) ＊3 . Miyata Y, Matsuo T, Ohba K, Mitsunari K, Mukae Y, Otsubo A, Harada J, Matsuda T, Kondo T, Sakai H: Present Status,Limitations and Future Directions of Treatment Strategies Using Fucoidan-Based Therapies in Bladder Cancer. Cancers
12(12): 2020. doi: 10.3390/cancers12123776. (IF: 6.639) ＊A-e-1
1 . Miyata Y, Ohba K, Matsuo T, Mitsunari K, Sakai H: A randomized, double-blinded clinical trial of royal jelly intake for
anticancer effects and suppressing adverse events in renal cell carcinoma patients treated with tyrosine kinase inhibitors. J.
Clin. Oncol. 38(6): 2020. (IF: 44.544) ＊2 . Matsuo T,Miyata Y,Mitsunari K,Ohba K, Sakai H: Long-term outcomes of patients with locally advanced bladder cancer
that underwent intra-arterial chemotherapy with/without radiotherapy for organ preservation. J. Clin. Oncol. 38(6): 2020.
(IF: 44.544) ＊3 . Ohtsubo A, Oshiro T, Kimura R, Miyazato M, Matsuo T, Miyata Y, Sakai H: OXIDATIVE STRESS INDUCESDETRUSOR UNDERACTIVITY AND URETHRAL DYSFUNCTION IN AGING RATS. J. Clin. Oncol. 203: E533-E534,
2020. (IF: 44.544) ＊4 . Ohtsubo A, Matsuo T, Mukae Y, Mitsunari K, Ohba K, Miyata Y, Sakai H: PREOPERATIVE NUTRITIONAL STATUS
OF TRANSURETHRAL LITHOTRIPSY AFFECTS DEVELOPMENT OF POSTOPERATIVE SYSTEMICINFLAMMATORY RESPONSE SYNDROME. J. Clin. Oncol. 203: E275, 2020. (IF: 44.544) ＊5 . Mukae Y, Miyata Y, Ohtsubo A, Yuno T, Mitsunari K, Matsuo T, Ohba K, Sakai H: KIBRA AND PHOSPHORYLATEDLATS-2 ARE NEGATIVELY ASSOCIATED WITH MALIGNANT AGGRESSIVENESS AND ARE PROGNOSTIC
INDICATORS IN PATIENTS WITH RENAL CELL CARCINOMA. J. Clin. Oncol. 203: E113-E114, 2020. (IF: 44.544)＊6 . Miyata Y, Yuno T, Mukae Y, Mitsunari K, Matsuo T, Ohba K, Sakai H, Otsubo A: INHIBITION OF E-TYPE
PROSTANOID RECEPTOR 1 INHIBITS THE MALIGNANT POTENTIAL OF PROSTATE CANCER CELLS IN AN
ANIMAL MODEL. J. Clin. Oncol. 203: E560, 2020. (IF: 44.544) ＊B

邦文B-a
1 . 宮田康好,松尾朋博,光成健輔,大庭康司郎,酒井英樹: 進行性尿路がんの2次治療における地域の医療・福祉サービ
スとの診療連携の有用性:生命予後やQoLへの影響. 泌尿器科紀要 66(4): 107-113, 2020.

2 . 望月 保志,大庭 康司郎,宮田 康好,酒井 英樹,大野 慎一郎,日高 匡章,江口 晋8: 複合臓器移植の経験と泌尿器科医の役割. 西日本泌尿器科 82(3): 350-356, 2020.
3 . 望月 保志,計屋 知彰,大庭 康司郎,宮田 康好,酒井 英樹: 【副甲状腺外科治療を極める】二次性副甲状腺機能亢進症の治療変遷と外科治療. 日本内分泌外科学会雑誌 37(4): 237-241, 2020.
4 . 計屋 知彰,酒井 英樹: 【副腎皮質疾患】長崎大学における副腎皮質癌の診療の実際 泌尿器科の立場から. 日本内分泌外科学会雑誌 37(4): 276-281, 2020.
B-b
1 . 酒井英樹1: 【前立腺がんの過剰診断・過剰治療の解決策】日本人の前立腺がん科 11(1): 1-6, 2020.

罹患率と死亡率の動向. 泌尿器2 . 計屋 知彰: 【前立腺癌治療の合併症・副作用マネージメント】骨修飾薬 投与前の注意と投与中の副作用対策.
Prostate Journal 7(1): 76-79, 2020.
3 . 酒井英樹4: 【泌尿器科診療の最新スタンダード-平成の常識は令和の非常識】内分泌疾患
ン症. 臨床泌尿器科 74(4): 190-193, 2020.

原発性アルドステロ

4 . 松尾 朋博,大坪 亜紗斗,迎 祐太,湯野 努,光成 健輔,大庭 康司郎,宮田 康好,酒井 英樹: 【夜間頻尿治療の最先端】夜間頻尿の治療 行動療法に関する最前線. 日本排尿機能学会誌 30(2): 107-113, 2020.
5 . 松尾朋博,宮田康好,酒井英樹: これが最新版!過活動膀胱のトリセツ〈過活動膀胱の治療と問題点〉行動療法. 臨床
泌尿器科 74(8): 570-574, 2020.
6 . 計屋 知彰,酒井 英樹: 【前立腺癌の薬物療法:ホルモン感受性癌から去勢抵抗性癌まで】新規ホルモン治療薬.
Prostate Journal 7(2): 171-175, 2020.
7 . 志田洋平, 酒井英樹: 【前立腺肥大症の新しい外科的治療の選択肢】前立腺肥大症の下部尿路症状に対する経尿道的水蒸気治療. 泌尿器科 12(4): 396-400, 2020.
8 . 計屋 知彰: JOURNAL IN JOURNAL-Focus On Your Direction-泌尿器科専門領域の最新情報(vol.5) 副腎腫瘍 褐色細胞腫の診断と治療. Uro-Lo: 泌尿器Care & Cure 25(6): 864-867, 2020.
9 . 中村裕子, 岡田みずほ, 小渕美樹子, 志田洋平, 酒井英樹: JOURNAL IN JOURNAL-Focus On Your Direction-泌尿器
科専門領域の最新情報(vol.5) 副腎腫瘍 副腎腫瘍手術患者の看護 病棟看護師の役割. Uro-Lo: 泌尿器Care &Cure 25(6): 868-873, 2020.
B-e-1
1 . 大庭 康司郎,酒井 英樹: 各科(外科、婦人科、泌尿器科)における側方リンパ節(骨盤リンパ節)郭清意義と実際 泌尿器癌に対する骨盤内リンパ節郭清の意義と実際. 日本外科系連合学会誌 45(5): 569, 2020.

論文研究業績集計表
論文数一覧
A-aA-bA-c2020
1830
学会発表数一覧
A-bA-aｼﾝﾎﾟｼﾞｳﾑ
2020

00A-d0A-e6SCI
23

合計
27B-a4B-b9

B-c0B-d0

B-e
1

A-b
学会

合計

B-aB-bｼﾝﾎﾟｼﾞｳﾑ

B-b学会

合計

総計

33023436

39

論文総数に係る教員生産係数
欧文論文総数
教員生産係数SCI 掲載論文数
教員生産係数論文総数（欧文論文）
欧文論文総数 （SCI 掲載論文）
2020
0.659
3.000
0.852
2.556
Impact Factor 値一覧
Impact Factor
教員当たりのImpact Factor 論文当たりのImpact Factor
2020
323.855
35.98414.081

合計
14総計41